Anticancer activity of Hypericum mysorense

Raghu H Chandrashekhar, P. Vasanth Raj, Venkata J Rao, N. Udupa

Research output: Chapter in Book/Report/Conference proceedingConference contribution

1 Citation (Scopus)

Abstract

Methanolic extracts of different parts of Hyperium mysorense (HM) (Hypericaceae) namely aerial parts (HMA), flowering tops (HMF), leaf (HML), root (HMR) and stem (HMS) were screened for its in vitro and in vivo anti cancer activities. The short term toxicity studies were carried out against Ehrlich Ascitic Carcinoma (EAC) cells. Different concentrations of the HM extracts (1000 μg/ml, 500 μg/ml, 250 μg/ml, 125 μg/ml, 62.5 μg/ml and 31.25 μg/ml) were tested against EAC cells and the viability of the cells were estimated by trypan blue dye exclusion method. HMF and HML showed better activity with CTC50 value of 375.39 ± 11.83 and 393.64 ± 12.28 μg/ml, respectively. In vivo antitumor studies were carried out for active HMF and HML extracts using EAC induced Swiss Albino mice model. Two different concentrations of HMF and HML were tested in vivo and compared with 5-Flurouracil (5-FU) as standard. The animals of the tumor control group inoculated with EAC survived for a period of 18.66 ± 0.65 days. The treatment with the HMF at 100 and 400 mg/kg increased the Average life span (ALS) of animals by 22.33 ± 1.28 and 26.16 ± 1.75 (p<0.01) days, respectively. HML at a dose of 100 and 400 mg/kg increased the ALS of animals by 19.50 ± 1.73 and 23.50 ± 1.18 days, respectively. The standard 5-FU at 20 mg/kg, significantly (p<0.001) increased the life span to 30.33 ± 1.02 (p<0.001) days.

Original languageEnglish
Title of host publication2nd International Conference on Biomedical and Pharmaceutical Engineering, ICBPE 2009 - Conference Proceedings
DOIs
Publication statusPublished - 2009
Event2nd International Conference on Biomedical and Pharmaceutical Engineering, ICBPE 2009 - Singapore, Singapore
Duration: 02-12-200904-12-2009

Conference

Conference2nd International Conference on Biomedical and Pharmaceutical Engineering, ICBPE 2009
CountrySingapore
CitySingapore
Period02-12-0904-12-09

Fingerprint

Flowering Tops
Hypericum
Animals
rilmenidine
Carcinoma
Cells
Clusiaceae
Toxicity
Tumors
Dyes
Trypan Blue
Antennas
Neoplasms
Cell Survival
Coloring Agents
Control Groups

All Science Journal Classification (ASJC) codes

  • Biomedical Engineering
  • Medicine(all)

Cite this

Chandrashekhar, R. H., Vasanth Raj, P., Rao, V. J., & Udupa, N. (2009). Anticancer activity of Hypericum mysorense. In 2nd International Conference on Biomedical and Pharmaceutical Engineering, ICBPE 2009 - Conference Proceedings [5384082] https://doi.org/10.1109/ICBPE.2009.5384082
Chandrashekhar, Raghu H ; Vasanth Raj, P. ; Rao, Venkata J ; Udupa, N. / Anticancer activity of Hypericum mysorense. 2nd International Conference on Biomedical and Pharmaceutical Engineering, ICBPE 2009 - Conference Proceedings. 2009.
@inproceedings{2942f124afbf415aa92729d9c390d395,
title = "Anticancer activity of Hypericum mysorense",
abstract = "Methanolic extracts of different parts of Hyperium mysorense (HM) (Hypericaceae) namely aerial parts (HMA), flowering tops (HMF), leaf (HML), root (HMR) and stem (HMS) were screened for its in vitro and in vivo anti cancer activities. The short term toxicity studies were carried out against Ehrlich Ascitic Carcinoma (EAC) cells. Different concentrations of the HM extracts (1000 μg/ml, 500 μg/ml, 250 μg/ml, 125 μg/ml, 62.5 μg/ml and 31.25 μg/ml) were tested against EAC cells and the viability of the cells were estimated by trypan blue dye exclusion method. HMF and HML showed better activity with CTC50 value of 375.39 ± 11.83 and 393.64 ± 12.28 μg/ml, respectively. In vivo antitumor studies were carried out for active HMF and HML extracts using EAC induced Swiss Albino mice model. Two different concentrations of HMF and HML were tested in vivo and compared with 5-Flurouracil (5-FU) as standard. The animals of the tumor control group inoculated with EAC survived for a period of 18.66 ± 0.65 days. The treatment with the HMF at 100 and 400 mg/kg increased the Average life span (ALS) of animals by 22.33 ± 1.28 and 26.16 ± 1.75 (p<0.01) days, respectively. HML at a dose of 100 and 400 mg/kg increased the ALS of animals by 19.50 ± 1.73 and 23.50 ± 1.18 days, respectively. The standard 5-FU at 20 mg/kg, significantly (p<0.001) increased the life span to 30.33 ± 1.02 (p<0.001) days.",
author = "Chandrashekhar, {Raghu H} and {Vasanth Raj}, P. and Rao, {Venkata J} and N. Udupa",
year = "2009",
doi = "10.1109/ICBPE.2009.5384082",
language = "English",
isbn = "9781424447640",
booktitle = "2nd International Conference on Biomedical and Pharmaceutical Engineering, ICBPE 2009 - Conference Proceedings",

}

Chandrashekhar, RH, Vasanth Raj, P, Rao, VJ & Udupa, N 2009, Anticancer activity of Hypericum mysorense. in 2nd International Conference on Biomedical and Pharmaceutical Engineering, ICBPE 2009 - Conference Proceedings., 5384082, 2nd International Conference on Biomedical and Pharmaceutical Engineering, ICBPE 2009, Singapore, Singapore, 02-12-09. https://doi.org/10.1109/ICBPE.2009.5384082

Anticancer activity of Hypericum mysorense. / Chandrashekhar, Raghu H; Vasanth Raj, P.; Rao, Venkata J; Udupa, N.

2nd International Conference on Biomedical and Pharmaceutical Engineering, ICBPE 2009 - Conference Proceedings. 2009. 5384082.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

TY - GEN

T1 - Anticancer activity of Hypericum mysorense

AU - Chandrashekhar, Raghu H

AU - Vasanth Raj, P.

AU - Rao, Venkata J

AU - Udupa, N.

PY - 2009

Y1 - 2009

N2 - Methanolic extracts of different parts of Hyperium mysorense (HM) (Hypericaceae) namely aerial parts (HMA), flowering tops (HMF), leaf (HML), root (HMR) and stem (HMS) were screened for its in vitro and in vivo anti cancer activities. The short term toxicity studies were carried out against Ehrlich Ascitic Carcinoma (EAC) cells. Different concentrations of the HM extracts (1000 μg/ml, 500 μg/ml, 250 μg/ml, 125 μg/ml, 62.5 μg/ml and 31.25 μg/ml) were tested against EAC cells and the viability of the cells were estimated by trypan blue dye exclusion method. HMF and HML showed better activity with CTC50 value of 375.39 ± 11.83 and 393.64 ± 12.28 μg/ml, respectively. In vivo antitumor studies were carried out for active HMF and HML extracts using EAC induced Swiss Albino mice model. Two different concentrations of HMF and HML were tested in vivo and compared with 5-Flurouracil (5-FU) as standard. The animals of the tumor control group inoculated with EAC survived for a period of 18.66 ± 0.65 days. The treatment with the HMF at 100 and 400 mg/kg increased the Average life span (ALS) of animals by 22.33 ± 1.28 and 26.16 ± 1.75 (p<0.01) days, respectively. HML at a dose of 100 and 400 mg/kg increased the ALS of animals by 19.50 ± 1.73 and 23.50 ± 1.18 days, respectively. The standard 5-FU at 20 mg/kg, significantly (p<0.001) increased the life span to 30.33 ± 1.02 (p<0.001) days.

AB - Methanolic extracts of different parts of Hyperium mysorense (HM) (Hypericaceae) namely aerial parts (HMA), flowering tops (HMF), leaf (HML), root (HMR) and stem (HMS) were screened for its in vitro and in vivo anti cancer activities. The short term toxicity studies were carried out against Ehrlich Ascitic Carcinoma (EAC) cells. Different concentrations of the HM extracts (1000 μg/ml, 500 μg/ml, 250 μg/ml, 125 μg/ml, 62.5 μg/ml and 31.25 μg/ml) were tested against EAC cells and the viability of the cells were estimated by trypan blue dye exclusion method. HMF and HML showed better activity with CTC50 value of 375.39 ± 11.83 and 393.64 ± 12.28 μg/ml, respectively. In vivo antitumor studies were carried out for active HMF and HML extracts using EAC induced Swiss Albino mice model. Two different concentrations of HMF and HML were tested in vivo and compared with 5-Flurouracil (5-FU) as standard. The animals of the tumor control group inoculated with EAC survived for a period of 18.66 ± 0.65 days. The treatment with the HMF at 100 and 400 mg/kg increased the Average life span (ALS) of animals by 22.33 ± 1.28 and 26.16 ± 1.75 (p<0.01) days, respectively. HML at a dose of 100 and 400 mg/kg increased the ALS of animals by 19.50 ± 1.73 and 23.50 ± 1.18 days, respectively. The standard 5-FU at 20 mg/kg, significantly (p<0.001) increased the life span to 30.33 ± 1.02 (p<0.001) days.

UR - http://www.scopus.com/inward/record.url?scp=77950850807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950850807&partnerID=8YFLogxK

U2 - 10.1109/ICBPE.2009.5384082

DO - 10.1109/ICBPE.2009.5384082

M3 - Conference contribution

AN - SCOPUS:77950850807

SN - 9781424447640

BT - 2nd International Conference on Biomedical and Pharmaceutical Engineering, ICBPE 2009 - Conference Proceedings

ER -

Chandrashekhar RH, Vasanth Raj P, Rao VJ, Udupa N. Anticancer activity of Hypericum mysorense. In 2nd International Conference on Biomedical and Pharmaceutical Engineering, ICBPE 2009 - Conference Proceedings. 2009. 5384082 https://doi.org/10.1109/ICBPE.2009.5384082